Breaking News Bar

Business News and Information

Gilead To Explore Trodelvy Drug Against Different Cancers After $21B Merger With Immunomedics

After initial reports emerged on Saturday about a potential acquisition deal, Gilead Sciences Inc. confirmed that it's set to purchase Immunomedics Inc.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear